Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: California Books, Miami, FL, U.S.A.
Condition: New.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. pp. 525.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: Books Puddle, New York, NY, U.S.A.
Condition: New. pp. 525 1st edition NO-PA16APR2015-KAP.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: As New. Unread book in perfect condition.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: Ria Christie Collections, Uxbridge, United Kingdom
£ 54.92
Quantity: Over 20 available
Add to basketCondition: New. In.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: New.
Language: English
Published by Taylor & Francis Ltd, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Paperback / softback. Condition: New. New copy - Usually dispatched within 4 working days.
Seller: Books Puddle, New York, NY, U.S.A.
Condition: New.
Language: English
Published by Chapman and Hall/CRC, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New.
Language: English
Published by Taylor & Francis Group, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: Books Puddle, New York, NY, U.S.A.
Condition: New. pp. 552.
Language: English
Published by Chapman and Hall/CRC 2014-11-14, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: Chiron Media, Wallingford, United Kingdom
Hardcover. Condition: New.
Language: English
Published by Chapman and Hall/CRC, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: New.
Language: English
Published by Chapman and Hall/CRC, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: California Books, Miami, FL, U.S.A.
Condition: New.
Language: English
Published by Apple Academic Press Inc., 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Hardback. Condition: New. New copy - Usually dispatched within 4 working days.
Language: English
Published by Chapman and Hall/CRC, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: Ria Christie Collections, Uxbridge, United Kingdom
£ 122.44
Quantity: Over 20 available
Add to basketCondition: New. In.
Language: English
Published by Chapman and Hall/CRC, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
£ 153.99
Quantity: Over 20 available
Add to basketCondition: As New. Unread book in perfect condition.
Hardcover. Condition: Brand New. 400 pages. 9.25x6.25x1.25 inches. In Stock.
Language: English
Published by Chapman and Hall/CRC, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: Mispah books, Redhill, SURRE, United Kingdom
Hardcover. Condition: Like New. Like New. book.
Language: English
Published by Chapman and Hall/CRC, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition.
Language: English
Published by Chapman and Hall/CRC, 2020
ISBN 10: 0367658984 ISBN 13: 9780367658984
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. PRINT ON DEMAND pp. 525.
Seller: AussieBookSeller, Truganina, VIC, Australia
Hardcover. Condition: new. Hardcover. Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. Print on Demand.
Seller: CitiRetail, Stevenage, United Kingdom
Hardcover. Condition: new. Hardcover. Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Johan A.K. Suykens is a professor at Katholieke Universiteit Leuven, Belgium, where he obtained a degree in electro-mechanical engineering and a Ph.D in applied sciences. He has been a visiting postdoctoral researcher at the University o.
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. PRINT ON DEMAND.
Language: English
Published by Taylor & Francis Group, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. Print on Demand pp. 552 This item is printed on demand.
Language: English
Published by Taylor & Francis Group, 2014
ISBN 10: 1482241390 ISBN 13: 9781482241396
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. PRINT ON DEMAND pp. 552.
Seller: preigu, Osnabrück, Germany
Buch. Condition: Neu. Headache Disorders | New Advances in Management and Treatment Strategies | Buch | Englisch | 2025 | MDPI AG | EAN 9783725843473 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.